Analyst Price Targets — CRBP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 22, 2026 11:05 am | Graig Suvannavejh | Mizuho Securities | $44.00 | $12.27 | TheFly | Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho |
| May 12, 2026 8:04 pm | Maury Raycroft | Jefferies | $33.00 | $11.43 | TheFly | Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies |
| October 29, 2025 12:49 pm | — | Mizuho Securities | $39.00 | $17.12 | TheFly | Corbus Pharmaceuticals price target raised to $39 from $32 at Mizuho |
| October 20, 2025 12:32 pm | — | Piper Sandler | $51.00 | $16.86 | TheFly | Corbus Pharmaceuticals price target raised to $51 from $35 at Piper Sandler |
| October 20, 2025 10:56 am | — | H.C. Wainwright | $40.00 | $19.32 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP) |
| December 2, 2024 9:09 am | Biren Amin | Piper Sandler | $35.00 | $17.82 | StreetInsider | Piper Sandler Starts Corbus Pharmaceuticals (CRBP) at Overweight |
| October 21, 2024 6:17 am | Jeff Jones | Oppenheimer | $60.00 | $18.41 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) |
| September 20, 2024 1:04 pm | Kalpit Patel | B.Riley Financial | $40.00 | $19.51 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Lowered to $40 at B.Riley |
| September 13, 2024 6:52 am | Graig Suvannavejh | Mizuho Securities | $74.00 | $51.58 | StreetInsider | Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) |
| August 7, 2024 7:44 am | Jeff Jones | Oppenheimer | $88.00 | $48.30 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Raised to $88 at Oppenheimer |
Latest News for CRBP
NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Leonardo Viana Nicacio, M.D.
Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Yuval Cohen outlined the company's near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by biotech analyst Amin Makarem.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
Corbus Pharmaceuticals NASDAQ: CRBP executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company's CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human papillomavirus, or HPV.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRBP.
U.S. House Trading
No House trades found for CRBP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.